Company: MIRA
Filing Date: 2025-06-24
Form Type: 8-K
Source: 0001641172-25-016285
Chunk: 1

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-24
Form: 8-K
Item: Item 8.01
Chunk 1
---
 SKNY-1’s effect in models of weight loss and nicotine addiction. The results are expected to inform
further development and potential regulatory planning, pending completion of the proposed acquisition.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                     MIRA                                          
  Dated:             By:                        /s/                
                     Name:                      Erez               
                     Title:                     Chief